Document Detail


Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?
MedLine Citation:
PMID:  16205019     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The term "lipid triad" or "atherogenic lipoprotein phenotype" has been introduced to describe a common form of dyslipidemia, characterized by three lipid abnormalities: increased plasma triglyceride levels, decreased HDL-cholesterol concentrations and the presence of small, dense LDL particles. It has been suggested that the clinical importance of the atherogenic lipoprotein phenotype probably exceeds that of LDL-cholesterol, because many more patients with coronary artery disease are found to have this trait than hypercholesterolaemia. There is a body of evidence that therapies effective against plasma HDL-cholesterol and triglycerides are associated with a strong reduction of cardiovascular risk; in addition, hypolipidemic treatment is able to increase LDL particle size and this increment correlates with regression of coronary stenosis. Recently, the Coordinating Committee of the National Cholesterol Education Program suggested that very high-risk patients may benefit from stronger lipid-lowering measures, a category of individuals that includes those with the atherogenic lipoprotein phenotype. Since the therapeutical modulation of each of the three components of the lipid triad is associated with a strong reduction in the risk of cardiovascular events, LDL size measurement may be extended as much as possible to patients at high risk of cardiovascular diseases.
Authors:
Manfredi Rizzo; Kaspar Berneis
Related Documents :
21291719 - Clinical commentary: reaching new targets in monotherapy and combination therapy.
1473909 - Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary...
1837559 - Influence of short term dietary cholesterol and fat on human plasma lp[a] and ldl levels.
2116079 - A three-year evaluation of metabolic changes in singaporean norplant acceptors.
17898099 - Hdl cholesterol, very low levels of ldl cholesterol, and cardiovascular events.
7418149 - Plasma high-density lipoprotein cholesterol, total cholesterol and triglyceride levels ...
3988649 - Influence of prefast feed intake on recovery from feed and water deprivation by beef st...
4868699 - The plasma lecithins:cholesterol acyltransferase reaction.
16460879 - Sucrose sham feeding on a binge schedule releases accumbens dopamine repeatedly and eli...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of atherosclerosis and thrombosis     Volume:  12     ISSN:  1340-3478     ISO Abbreviation:  J. Atheroscler. Thromb.     Publication Date:  2005  
Date Detail:
Created Date:  2005-10-05     Completed Date:  2006-01-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9506298     Medline TA:  J Atheroscler Thromb     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  237-9     Citation Subset:  IM    
Affiliation:
Department of Clinical Medicine and Emerging Diseases, University of Palermo, Via del Vespro 141, Palermo 90127, Italy. mrizzo@unipa.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / therapeutic use
Atherosclerosis / blood*
Cardiovascular Diseases / blood,  prevention & control
Dyslipidemias / blood,  complications*,  drug therapy
Humans
Lipoproteins, LDL / blood*,  classification
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Lipoproteins, LDL

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Microwave-assisted cross-coupling reaction of alkynylstibanes with aryl iodides in the presence of a...
Next Document:  Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japane...